Study ofan association between chronic obstructive pulmonary diseases and types 1 and 2 diabetes

Terapevticheskii Arkhiv

Volumn 82, Issue 3, 2010, Pages 13-18

  Kobylyansky, V I ^a,b   Yu Babadzhanova, G ^a,b   Suntsov, Yu I ^a,b  

^a Federal Biomedical Agency   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Association of diseases; Asthma; Chronic obstructive pulmonary disease; Diabetes; Mutual prevalence

Indexed keywords

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

ADULT; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES;

EID: 77952073329     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. 1. Concannon P., Erlich H. A., Julier C. et al. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1, 435 multiplex families. Diabetes 2005; 54 (10): 2995-3001. (Pubitemid 41401098)
2. Rich S. S., Concannon P., Erlich H. et al. The Type 1 Diabetes Genetics Consortium. Ann. N. Y. Acad. Sci. 2006; 1079: 1-8.
3. Pauwels R. A., Buist A. S., Ma P. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir. Care 2001; 46: 798-825.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Workshop report. The 2006 reportb is available on www.goldcopd.com.
5. (see also UPDATED 2007).
6. Global Initiative forAsthma (GINA). Global strategy for asthma management and prevenrtion. 2004. www.ginasthma.org; accessed January. 2007.
7. Majori M., Corradi M., Caminati A. et al. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 1999; 103 (3, pt1): 458-462.
8. Chung K. F. Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl. 2001; 34: 50S-59S.
9. Oudijk E., Lammers J., Koenderman L. et al. Systemic inflammation in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 5S-13S.
10. Perng D. W., Wu C. C., Su K. C. et al. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility. Lung 2006; 184 (4): 217-222.
11. 11. Groenewegen K. H., Postma D. S., Hop W. C. et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008; 133 (2): 350-357. (Pubitemid 351272391)
12. Renauld J. C. New insights into the role of cytokines in asthma. J. Clin. Pathol. 2001; 54: 577-589.
13. 13. Pradhan A. D., Manson J. E., Rifai N. et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J. A. M. A. 2001; 286: 327-334. (Pubitemid 32656163)
14. 14. Hu F. B., Meigs J. B., Li T. Y. et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700. (Pubitemid 38270639)
15. Wouters E. F. M., Karin H. G., Mieke A. D. et al. Systemic inflammation in chronic obstructive pulmonary disease. The role of exacerbations. Proc. Am. Thorac. Soc. 2007; 4: 626-634.
16. Dahl M., Vestbo J., Lange P. et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175 (3): 250-255.
17. Wouters E. F. Chronic obstructive pulmonary disease. 5. Systemic effects of COPD. Thorax 2002; 57: 1067-1070.
18. Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc. Nutr. Soc. 1999; 58: 321-328.
19. Mador M. J. Muscle mass, not body weight, predicts outcome in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 787-789.
20. Schols A. M., Buurman W. A., Staal van den Brekel A. J. et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-824.
21. Pitsiou G., Kyriazls G., Hatzizbi O. et al. Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir. Med. 2002; 96: 594-598.
22. Takabatake N., Nakamura H., Abe S. The relationship between chronic hypoxemia and activation of the tumor necrosis factoralpha system in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1179-1184.
23. Hotamisligil G. S., Murray D. L., Choy L. N., Spiegelman B. M. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA 1994; 91: 4854-4858.
24. Hotamisligil G. S. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 1999; 245: 621-625.
25. Lazarus R., Sparrow D., Weiss S. T. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. Eur. Respir. J. 1998; 123: 641-645.
26. Engstrom G., Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabet. Med. 2002; 19: 167-170.
27. Rahman I., Gilmour P. S., Jimenez L. A., MacNee W. Oxidative stress and TNF-alpha induce histone acetylation and NFkappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol. Cell. Biochem. 2002; 234-235: 239-248.
28. Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J. Biochem. Mol. Biol. 2003: 36: 95-109.
29. Rosen P., Nawroth P. P., King G. et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCOMCBN, the American Diabetes Association and the German Diabetes Society. Diabet. Metab. Res. Rev. 2001; 7: 189-212.
30. Daniel M., Cargo M. Association between smoking, insulin resistance and beta-cell function in a Northwestern First Nation. Diabet. Med. 2004; 21 (2): 188-193.
31. Hota Y., Yatsuya H., Toyoshima H. et al. Low leptin but high insulin resistance of smokers in Japanese men. Diabet. Res. Clin. Pract. 2008; 81 (3): 358-364.
32. Sethi S., Moloney J., Crove L. et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173 (9): 991-998.
33. Abusrlwil H., Stockley R. A. The interaction of host and pathogen factors in chronic obstructive pulmonary disease exacerbations and their role in tissue damage. Proc. Am. Thorac. Soc. 2007; 4 (8): 611-617.
34. Blackburn D., Hux J., Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J. Gen. Intern. Med. 2002; 17: 717-720.
35. Renauld J. C. New insights into the role of cytokines in asthma. J. Clin. Pathol. 2001; 54 (8): 577-589.
36. Cardwell C. R., Shields M. D., Carson D. J., Patterson C. C. A meta-analysis of the association between childhood type 1 diabetes and atopic disease. Diabet. Care 2003; 26 (9): 2568-2574.
37. 42. Rosenbauer J., Herzig P., Giani G. Atopic eczema in early childhood could be protective against type 1 diabetes. Diabetologia 2003; 46 (6): 784-788. (Pubitemid 36831406)